华熙生物: 华熙生物关于2025年第二季度计提大额资产减值准备的公告

Overview - The company announced a significant asset impairment provision for the second quarter of 2025, totaling 4,837.27 million RMB, which includes credit impairment losses of 599.86 million RMB and inventory impairment losses of 4,237.41 million RMB [1][2][4] Asset Impairment Provision Summary - The company recognized credit impairment losses of 599.86 million RMB, with accounts receivable bad debt provision amounting to 688.00 million RMB and a reversal of other receivables bad debt provision of 88.14 million RMB [2] - The total bad debt provision for the second quarter reached 599.86 million RMB, with the balance of accounts receivable bad debt provision at 12,430.66 million RMB, representing 18.22% of the accounts receivable balance [2] - The company also recognized inventory impairment losses of 4,237.41 million RMB, with the total balance of inventory impairment provision at 8,047.73 million RMB, accounting for 6.44% of the inventory balance [2] Impact on Financials - The asset impairment provision will reduce the company's total profit for the second quarter of 2025 by 4,837.27 million RMB, but it will not change the overall profit or loss situation of the company [3][4] - The provision reflects the company's actual situation and complies with accounting standards, ensuring that it does not harm the interests of the company and its shareholders [4]